Letermovir for children after a kidney transplant
Treatments studied
Part of Infections, Kidney & urinary clinical trials.
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a kidney transplant and it's between 4 weeks and about a year ago.
- Your kidney function is stable.
- A recent blood test shows you do not have CMV (a virus) in your blood.
- You can swallow letermovir tablets or pellets, or take pellets through a feeding tube.
- You weigh at least 2.5 kilograms (about 5.5 pounds) and less than 40 kilograms (about 88 pounds).
- You do not have any other serious infections or conditions that affect how your body absorbs medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This study tests a drug called letermovir to see if it can help prevent a common virus called CMV from causing problems after your transplant. It's for people who have had a kidney or liver transplant and carry the virus.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
Hear when a new Cytomegalovirus Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.